Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604068 | 0.92 | KMT2A (0.31) | — | |
| SCHEMBL5604077 | 0.92 | KMT2A (0.31) | — | |
| SCHEMBL5604089 | 0.92 | KMT2A (0.31) | — | |
| SCHEMBL11229608 | 0.77 | — | — | |
| SCHEMBL11148795 | 0.74 | — | — | |
| SCHEMBL3863533 | 0.73 | — | — | |
| SCHEMBL3863532 | 0.73 | — | — | |
| SCHEMBL3863529 | 0.73 | — | — | |
| SCHEMBL10454264 | 0.72 | KMT2A (0.30) | — | |
| SCHEMBL5603837 | 0.69 | KMT2A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2903969-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053665-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | NOS3 2835/4885NOS1 3445/4885NOS2 3512/4885 |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | NOS3 1851/4885NOS1 2228/4885NOS2 2017/4885 |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, POLRMT | NOS3 2816/4885NOS1 2177/4885NOS2 2235/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | NOS3 613/4885NOS1 760/4885NOS2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.